Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Ophthalmology. 2021 Mar 4;128(9):1337–1345. doi: 10.1016/j.ophtha.2021.02.024

Table 3.

Results from linear mixed models comparing the difference in quality of life at the primary endpoint by treatment group and by treatment successa,b

A. Methotrexate (vs. Mycophenolate Mofetil) B. Treatment Success (vs Treatment Failure)

Coef. 95% CI P-value Coef. 95% CI P-value
Vision-related QoL c
 NEI-VFQ 2.2 −1.4-5.8 0.23 9.8 6.2-13.5 <0.001
 IND-VFQ 3.9 −1.5-9.3 0.16 15.6 10.2-20.8 <0.001
Health-related QoL d
 PCS 0.6 −1.3-2.6 0.51 3.6 1.6-5.5 <0.001
 MCS −0.5 −3.2-2.2 0.72 3.7 1.0-6.5 <0.001
a

Primary endpoint was defined as 6 months from the baseline visit (or the time of treatment failure prior to 6 months)

b

All multivariable models controlled for baseline quality of life, age, sex, and site (random effect)

c

Vision-related quality of life scales: NEI-VFQ - National Eye Institute Visual Functioning Questionnaire; IND-VFQ - Indian Vision Function Questionnaire (Indian participants only)

d

Health-related quality of life scales: PCS - physical component score of the Medical Outcomes Study 36-Item Short Form Survey (PCS SF-36v2); MCS - mental component score of the Medical Outcomes Study 36-Item Short Form Survey (MCS SF-36v2)